Skip to main content

Advertisement

SpringerLink
Log in

Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Background

Familial Mediterranean fever (FMF) patients suffer from chronic complications of disease such as AA amyloidosis, chronic arthritis, and spondylitis. Reduced quality of life (QoL) is a feature of chronic diseases but it is also impaired in patients with FMF. Despite the regular use of colchicine at a maximal dose, about 10% of patients do not respond well or resistant to colchicine (crFMF). IL-1 inhibitors have been shown to be effective in controlling attacks in crFMF patients. Herein, we aimed to investigate QoL changes of crFMF patients with IL-1 inhibitors.

Methods

All patients were prospectively monitored for the frequency, duration, severity of attacks, patient global assessments (Visual Analog Scale; VAS), and laboratory features. Either anakinra or canakinumab was used as IL-1 antagonist treatments. Demographic information, MEFV gene mutations, attack characteristics, and previous treatments were registered. Short form-36 (SF-36) quality of life scale was implemented by the interviewer for evaluating the QoL before and 3 months after the treatment.

Results

A total of 44 patients were included in this study. Striking improvements were detected in frequency, duration, and VAS severity of attacks (p < 0.001). In the comparison of pre- and post-treatment, SF-36 sub-components significant improvements were observed on physical function, role limitation due to physical difficulty, role limitation due to emotional problem, energy, emotional well-being, social function, pain, general health, and health change.

Conclusions

In conclusion, IL-1 antagonists prevent attacks and improve QoL of crFMF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sari I, Birlik M, Kasifoglu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheumatol 1(1):21–33. https://doi.org/10.5152/eurjrheum.2014.006

    Article  PubMed  PubMed Central  Google Scholar 

  2. Shohat M, Halpern GJ (2011) Familial Mediterranean fever--a review. Genet Med 13(6):487–498. https://doi.org/10.1097/GIM.0b013e3182060456

    Article  PubMed  Google Scholar 

  3. Tufan A, Ozturk MA (2017) Ailesel Akdeniz Ateşi: Güncel Tedavi Yaklaşımları. Turkiye Klinikleri J Rheumatol-Special Topics 10(1):37–45

    Google Scholar 

  4. Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651. https://doi.org/10.1136/annrheumdis-2015-208690

    Article  CAS  PubMed  Google Scholar 

  5. Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, Perski O, Bornstein G, Grossman C, Harari G, Lidar M, Livneh A (2017) Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 69(4):854–862. https://doi.org/10.1002/art.39995

    Article  CAS  Google Scholar 

  6. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Kone-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G (2018) Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 378(20):1908–1919. https://doi.org/10.1056/NEJMoa1706314

    Article  PubMed  Google Scholar 

  7. Varan O, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, Goker B, Tufan A (2018) Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol:1–4. https://doi.org/10.1080/14397595.2018.1457469

  8. Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, Katz SI, Kastner DL (2011) Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 34(5):755–768. https://doi.org/10.1016/j.immuni.2011.02.020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10(2):417–426

    Article  CAS  PubMed  Google Scholar 

  10. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R (2013) IL-1beta biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol 45(1):117–130. https://doi.org/10.1007/s12016-013-8358-y

    Article  CAS  PubMed  Google Scholar 

  11. Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U, Karadag O, Hayran M, Ertenli AI, Bozkurt A, Kiraz S (2007) Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 34(7):1540–1544

    CAS  PubMed  Google Scholar 

  12. Deger SM, Ozturk MA, Demirag MD, Aslan S, Goker B, Haznedaroglu S, Onat AM (2011) Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol Int 31(5):623–628. https://doi.org/10.1007/s00296-009-1334-4

    Article  PubMed  Google Scholar 

  13. Giese A, Kurucay M, Kilic L, Ornek A, Sendur SN, Lainka E, Henning BF (2013) Quality of life in adult patients with Familial Mediterranean fever living in Germany or Turkey compared to healthy subjects: a study evaluating the effect of disease severity and country of residence. Rheumatol Int 33(7):1713–1719. https://doi.org/10.1007/s00296-012-2622-y

    Article  PubMed  Google Scholar 

  14. Press J, Neumann L, Abu-Shakra M, Bolotin A, Buskila D (2000) Living with a child with familial Mediterranean fever: does it affect the quality of life of the parents? Clin Exp Rheumatol 18(1):103–106

    CAS  PubMed  Google Scholar 

  15. Sahin S, Yalcin I, Senel S, Ataseven H, Uslu A, Yildirim O, Semiz M (2013) Assesment life quality of familial Mediterranean fever patients by short form-36 and its relationship with disease parameters. Eur Rev Med Pharmacol Sci 17(7):958–963

    CAS  PubMed  Google Scholar 

  16. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885. https://doi.org/10.1002/1529-0131(199710)40:10&lt;1879::AID-ART23&gt;3.0.CO;2-M

    Article  CAS  PubMed  Google Scholar 

  17. Demiral Y, Ergor G, Unal B, Semin S, Akvardar Y, Kivircik B, Alptekin K (2006) Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health 6:247. https://doi.org/10.1186/1471-2458-6-247

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I Conceptual framework and item selection. Med Care 30(6):473–483

    Article  PubMed  Google Scholar 

  19. Kocyigit HAO, Fisek G, Olmez N, Memis A (1999) Validity and reliability of Turkish version of short form 36: a study of a patients with romatoid disorder. J Drug Ther (in Turkish) 12:102–106

    Google Scholar 

  20. Buskila D, Zaks N, Neumann L, Livneh A, Greenberg S, Pras M, Langevitz P (1997) Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol 15(4):355–360

    CAS  PubMed  Google Scholar 

  21. Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, Kasapcopur O, Kasifoglu T, Kisacik B, Ozdogan H, Tunca M, Acikel C, Vasculitis FMFA, Orphan disease research in pediatric r, Turkish FMFsg (2014) FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 73(5):897–901. https://doi.org/10.1136/annrheumdis-2013-204719

    Article  PubMed  Google Scholar 

  22. Gul A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, Sevgi S (2015) Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther 17:243. https://doi.org/10.1186/s13075-015-0765-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hashkes PJ, Spalding SJ, Hajj-Ali R, Giannini EH, Johnson A, Barron KS, Weisman MH, Pashinian N, Reiff AO, Samuels J, Wright D, Lovell DJ, Huang B (2014) The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int 2014:854842. https://doi.org/10.1155/2014/854842

    Article  PubMed  PubMed Central  Google Scholar 

  24. Duruoz MT, Unal C, Bingul DK, Ulutatar F (2018) Fatigue in familial Mediterranean fever and its relations with other clinical parameters. Rheumatol Int 38(1):75–81. https://doi.org/10.1007/s00296-017-3882-3

    Article  PubMed  Google Scholar 

  25. Makay B, Emiroglu N, Unsal E (2010) Depression and anxiety in children and adolescents with familial Mediterranean fever. Clin Rheumatol 29(4):375–379. https://doi.org/10.1007/s10067-009-1330-9

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Gazi University, 06100, Ankara, Turkey

    Ozkan Varan, Hakan Babaoglu, Nuh Atas, Reyhan Bilici Salman, Hasan Satis, Mehmet Akif Ozturk, Seminur Haznedaroglu, Berna Goker & Abdurrahman Tufan

  2. Erzurum Regional Education and Research Hospital, Erzurum, Turkey

    Hamit Kucuk

Authors
  1. Ozkan Varan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamit Kucuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hakan Babaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nuh Atas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reyhan Bilici Salman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hasan Satis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mehmet Akif Ozturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seminur Haznedaroglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Berna Goker
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Abdurrahman Tufan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ozkan Varan.

Ethics declarations

For use of IL-1 antagonists, off-label permission was obtained from regulatory authority and local ethics committee approved the study.

Disclosures

None.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Varan, O., Kucuk, H., Babaoglu, H. et al. Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients. Clin Rheumatol 38, 1125–1130 (2019). https://doi.org/10.1007/s10067-018-4384-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4384-8

Keywords

Search

Navigation